Works by Hallas, Jesper


Results: 278
    1
    2
    3
    4
    5

    Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program.

    Published in:
    Pharmacoepidemiology & Drug Safety, 2024, v. 33, n. 5, p. 1, doi. 10.1002/pds.5799
    By:
    • de Vogel, Stefan;
    • Seeger, John D.;
    • Arana, Alejandro;
    • Margulis, Andrea V.;
    • McQuay, Lisa J.;
    • Perez‐Gutthann, Susana;
    • Hallas, Jesper;
    • Kristiansen, Nina Sahlertz;
    • Linder, Marie;
    • Odsbu, Ingvild;
    • Suehs, Brandon;
    • Xu, Yihua;
    • Uribe, Claudia;
    • Appenteng, Kwame;
    • Robinson, Noah Jamie
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis.

    Published in:
    Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 4, p. 482, doi. 10.1002/pds.5191
    By:
    • Morales, Daniel R.;
    • Macfarlane, Tatiana;
    • MacDonald, Thomas M.;
    • Hallas, Jesper;
    • Ernst, Martin Thomsen;
    • Herings, Ron M. C.;
    • Smits, Elisabeth;
    • Overbeek, Jetty A.;
    • Mitchell, Lyn;
    • Morant, Steven;
    • Mackenzie, Isla;
    • Doney, Alexander S. F.;
    • Robertson, Chris;
    • Bennie, Marion;
    • Wei, Li;
    • Nicholson, Lizzie;
    • Morris, Carole;
    • Flynn, Robert W. F.
    Publication type:
    Article
    23

    Association of Low-Dose Quetiapine and Diabetes.

    Published in:
    JAMA Network Open, 2021, v. 4, n. 5, p. e213209, doi. 10.1001/jamanetworkopen.2021.3209
    By:
    • Højlund, Mikkel;
    • Lund, Lars C.;
    • Andersen, Kjeld;
    • Correll, Christoph U.;
    • Hallas, Jesper
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.

    Published in:
    2021
    By:
    • Hoffman, Veena;
    • Hallas, Jesper;
    • Linder, Marie;
    • Margulis, Andrea V.;
    • Suehs, Brandon T.;
    • Arana, Alejandro;
    • Phiri, Kelesitse;
    • Enger, Cheryl;
    • Horter, Libby;
    • Odsbu, Ingvild;
    • Olesen, Morten;
    • Perez-Gutthann, Susana;
    • Xu, Yihua;
    • Kristiansen, Nina Sahlertz;
    • Appenteng, Kwame;
    • de Vogel, Stefan;
    • Seeger, John D.;
    • the mirabegron PMR-PASS study group;
    • Seeger, John;
    • Bahmanyar, Shahram
    Publication type:
    journal article
    33
    34
    35
    36
    37
    38

    Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma.

    Published in:
    2016
    By:
    • Pottegård, Anton;
    • Schmidt, Sigrún Alba Johannesdottir;
    • Olesen, Anne Braae;
    • Achacoso, Ninah;
    • Van Den Eeden, Stephen K;
    • Hallas, Jesper;
    • Sørensen, Henrik Toft;
    • Friis, Søren;
    • Habel, Laurel A;
    • Pottegård, Anton;
    • Schmidt, Sigrún Alba Johannesdottir;
    • Sørensen, Henrik Toft;
    • Friis, Søren
    Publication type:
    journal article
    39
    40
    41
    42
    43

    Ischemic Stroke and Systemic Embolism in Warfarin Users With Atrial Fibrillation or Heart Valve Replacement Exposed to Dicloxacillin or Flucloxacillin.

    Published in:
    Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 607, doi. 10.1002/cpt.1662
    By:
    • Hellfritzsch, Maja;
    • Lund, Lars Christian;
    • Ennis, Zandra;
    • Stage, Tore;
    • Damkier, Per;
    • Bliddal, Mette;
    • Jensen, Peter Bjødstrup;
    • Henriksen, Daniel;
    • Ernst, Martin Thomsen;
    • Olesen, Morten;
    • Broe, Anne;
    • Kristensen, Kasper Bruun;
    • Hallas, Jesper;
    • Pottegård, Anton
    Publication type:
    Article
    44
    45
    46
    47
    48
    49
    50